Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Newbury Pharmaceuticals AB's Pretax Margin % or its related term are showing as below:
OSTO:NEWBRY'
s Pretax Margin % Range Over the Past 10 Years
Min: -265.9 Med: -189.28 Max: -41.84
Current: -86.05
OSTO:NEWBRY's Pretax Margin % is ranked worse than 89.67% of 958
companies
in the Drug Manufacturers industry
Industry Median: 7.455
vs OSTO:NEWBRY: -86.05
Newbury Pharmaceuticals AB (OSTO:NEWBRY) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Newbury Pharmaceuticals AB Pretax Margin % Related Terms
Newbury Pharmaceuticals AB Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NEWBRY vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newbury Pharmaceuticals AB (OSTO:NEWBRY) has a Pretax Margin % of -53.90% as of Feb. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Newbury Pharmaceuticals AB and its competitors. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #859 out of 958 companies in the Drug Manufacturers industry, placing it in the top 89.7%.
Is Newbury Pharmaceuticals AB's Pretax Margin % too high?
Newbury Pharmaceuticals AB's current Pretax Margin % is -53.90%. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #859 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #859 out of 958 companies for Pretax Margin %. This places Newbury Pharmaceuticals AB in the lower half of its industry. The industry median Pretax Margin % is 7.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.46, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current Pretax Margin % is -53.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB (OSTO:NEWBRY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.20, compared to a current price of kr2.48 — trading 22.5% below its estimated fair value. The current Pretax Margin % is -53.90%. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (OSTO:NEWBRY), the current Pretax Margin % is -53.90% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20.
GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.
Key valuation signals for OSTO:NEWBRY:
Pretax Margin %: -53.90%
GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score
Get the complete analysis for OSTO:NEWBRY
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NEWBRY has been successfully added to your 
